

## **Research** Article

# Systematic Review of the Efficacy and Safety of Shuxuening Injection in the Treatment of Unstable Angina

Genhao Fan (b,<sup>1</sup> Menglin Liu (b,<sup>1</sup> Jia Liu (b,<sup>2</sup> Xixi Chen (b,<sup>1</sup> and Yuhong Huang (b<sup>2</sup>

<sup>1</sup>Tianjin University of Chinese Medicine, Tianjin 301617, China <sup>2</sup>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Correspondence should be addressed to Yuhong Huang; 819434062@qq.com

Received 25 November 2020; Revised 27 September 2021; Accepted 26 November 2021; Published 15 February 2022

Academic Editor: Im Hee Shin

Copyright © 2022 Genhao Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to systematically review the efficacy and safety of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina. Randomized controlled trials of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina were searched by the computer system from PubMed, EMBASE, Cochrane Library, VIP, CNKI, Wanfang Database, and Chinese Biomedical Database since the establishment of the database until June 2020, according to the inclusion and exclusion criteria for the selection of literature, using Rev Man5.3 Meta-analysis Software. The 28 randomized controlled trials were included, with a total of 3,127 patients. Meta-analysis results showed that Shuxuening injection combined with conventional western medicine was effective in improving the clinical efficacy of angina pectoris (RR = 1.23, 95% CI [1.19, 1.27], P<0.00001), improvement of ECG (RR = 1.31, 95% CI [1.23, 1.40], P < 0.00001), reduction of angina pectoris attack frequency (MD = -1.28, 95% CI [-1.88, -0.67], P < 0.0001), duration of angina (MD = -3.36, 95% CI [-3.69, -3.03], P < 0.00001), nitroglycerin dosage (MD = -0.39, 95% CI [-0.65, -0.13], P = 0.003), C-reactive protein (MD = -2.72, 95% CI [-3.41, -2.03], P < 0.00001), BNP (MD = -23.33, 95% CI [-27.87, -18.79], P < 0.00001), lower triglycerides (MD = -0.72, 95% CI [-1.05, -0.38], P < 0.0001), total cholesterol (MD = -1.39, 95% CI [-1.84, -0.94], P < 0.00001), and LDL cholesterol (MD = -1.20, 95% CI [-2.12, -0.29], P = 0.01) which is better than that of control group. The effect on raising HDL cholesterol was comparable between the two groups (MD = 0.49, 95% CI [-0.06, 1.04], P = 0.08) and the incidence of adverse reactions to differences had no statistical significance (RR = 0.99, 95% CI [0.54, 1.81], P = 0.97). The Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina has clear efficacy and a certain degree of safety, so it is recommended for clinical application.

## 1. Introduction

Unstable angina (UA) is an acute coronary syndrome between stable angina and acute myocardial infarction [1], which is mainly manifested as pain in the anterior cardiac region and posterior sternum. Its instability is mainly affected by native coronary artery lesions, and it is characterized by a progressive exacerbation of angina symptoms and prolonged duration of pain. Thrombosis is mainly caused by the rupture of atherosclerotic plaques or the erosion of the mural walls in coronary arteries [2, 3]. The effective treatment of unstable angina can improve the survival rate and quality of life of the patients. Western medicine treatment mainly includes treating stable plaque, using antiplatelet and antithrombotic drugs, reducing myocardial injury brought about by ischemia and reperfusion, and preventing the progression of coronary atherosclerosis. With the popularity of traditional Chinese medicine, it plays a more and more important role in cardiovascular emergencies. The core theory of traditional Chinese medicine is the overall concept and treatment based on syndrome differentiation. It is supposed that it would have an excellent long-term efficacy, complementary with Western medicine treatment, giving full play to each other's advantages and improving the survival rate and quality of life of patients.

The Shuxuening injection is a prescribed herbal medicine of Ginkgo biloba extract; EGb aqueous solution is made by sterilization, with the main effective components such as flavonoid glycosides and terpenoid lactone active substances, including quercetin, galangal, different rat Li Su, Ginkgo biloba lactone, and Ginkgo lactone [4], to relax coronary artery, improve microcirculation, enhance body hypoxia tolerance, and reduce blood viscosity. However, the most clinical studies were clinical experience summary, lacking prospective trial with large sample size, and their pharmacological active components, and pharmacological mechanism still needs more studies to illustrate. In this study, the efficacy and safety of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina were systematically evaluated to clear the clinical efficacy of Shuxuening injection.

#### 2. Methods

The meta-analysis followed the standard set of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol for this study was registered with CRD42021223531.

2.1. Literature Sources. Randomized controlled trials of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina were searched by the computer system from PubMed, EMBASE, Cochrane Library, VIP, CNKI, Wanfang Database, and Chinese Biomedical Database since the establishment of the database until June 2020. To find out which words are used in China, Shuxuening injection, unstable angina, and any word in English are searched using the search terms "Shuxuening injection" and "Unstable angina."

#### 2.2. Inclusion Criteria

- Study type: a clinical randomized controlled trial of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina was conducted.
- (2) According to "2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction," the subjects met the diagnostic criteria, and there were no restrictions on age, gender, alcohol, and tobacco history.
- (3) The control group focused on the same conventional Western medicine only. The main drugs were anticoagulation, antiplatelet aggregation, receptor blockers, nitrates, angiotensin-converting enzyme inhibitors (ACEIs), statins, and other drugs, which are used to reduce lipid, while the treatment group was treated with the Shuxuening injection combined with conventional Western medicine.
- (4) The primary clinical indicators are frequency of angina attacks, duration of angina, nitroglycerin dosage, ECG improvement, and secondary clinical indicators are angina clinical curative effect, blood

lipids (triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol), C-reactive protein, BNP (brain natriuretic peptide), and adverse drug reactions or adverse events.

2.3. Exclusion Criteria. The intervention measures did not meet the inclusion criteria, the diagnosis was not clear, and the course of treatment was not clear; the experimental group only used Shuxuening injection or Western medicine compared with the control group, and the control group used other proprietary Chinese medicine; the outcome indicators did not include any other adverse reactions.

2.4. Literature Screenings, Data Extraction, and Methodological Quality Evaluation. Two investigators independently read the full text of the literature to extract relevant information. The information extraction included the basic information of the literature, intervention methods, risk of bias assessment (type of study design, randomisation method, allocation concealment, blinding, completeness of data information, and outcome reporting), relevant outcome indicators, and adverse effects. When the two parties disagreed on the inclusion of the literature, the discussion was referred to a third party to judge the final literature for information extraction. The included literature was evaluated against the Cochrane Handbook [5] risk of bias assessment tool for clinical randomised controlled trials with entries on randomisation methods, allocation concealment, blinded implementation, outcome data completeness, selective reporting, and other sources of bias.

2.5. Statistical Treatments. RevMan 5.3 Software was used only for the statistical analysis of the included literature review on research data. If significant heterogeneity was found in the experimental results ( $I^2 \ge 50\%$ ), the randomeffects model was used only for the meta-analysis. If the experimental results showed good homogeneity ( $I^2 < 50\%$ ), the fixed-effects model was used for the metaanalysis. The risk ratio (RR) was used as the combined statistic for the meta-analysis, while the mean difference (MD) was used as the statistic for the meta-analysis. If more than 10 references were included in a specified outcome indicator, a funnel plot was used to analyze whether there was publication bias.

#### 3. Results

3.1. Literature Retrieval. A total of 330 references were retrieved. The titles retrieved from various databases were imported into NoteExpress 3.2.0 Software. A total of 28 titles were finally included after screening [6-33]. The literature screening flow chart and results are shown in Figure 1.

*3.2. Basic Characteristics of Literature Research.* A total of 28 references [6–33] were listed, with a total of 3127 patients. The number of cases in the experimental group was 1584 and that in the control group was 1543. The results are as follows:



FIGURE 1: Document selection process and results.

twenty-five [7, 9–21, 23–33] articles observed the clinical efficacy of angina, five [8, 10, 26, 27] articles observed the frequency of angina, five [6, 8, 10, 13, 27] articles observed the duration of angina, three [17, 22, 27] articles observed the amount of nitroglycerin, 13 [7, 12, 14–16, 20–23, 29, 31–33] articles observed the ECG improvement, and three [11, 16, 29] articles observed the blood lipid. C-reactive protein was observed in 9 [8, 10, 11, 13–16, 18, 26] papers, brain natriuretic peptide was observed in 4 [8, 10, 13, 18] papers, and adverse reactions were observed in 16 [7, 13, 16, 19–25, 27, 29–33] papers, as shown in Table 1.

3.3. Quality Evaluation of Included Literature. The works of literature included in this systematic review were evaluated using the Cochrane Handbook. A total of 28 studies were included, 4 studies [10, 12, 13, 18] were grouped using the random number table method, the remaining 24 studies mentioned randomisation but did not specifically describe it, none of the included literature mentioned allocation concealment or blinding, none of the included literature had case loss or dropouts, all studies had complete data, and specific evaluation information on risk of bias is shown in Figure 2.

#### 3.4. Meta-Analysis Results

3.4.1. Frequency of Angina Attack. There were 5 articles [8, 10, 13, 26, 27] that observed the frequency of angina, and the heterogeneity test showed that there was significant heterogeneity among the results of studies (P < 0.00001,  $I^2 = 92\%$ ); therefore, a random-effects model was used for the meta-analysis, and the results showed a statistically significant difference (MD = -1.28, 95% CI [-1.88, -0.67], P < 0.0001), suggesting that the Shuxuening injection combined with conventional Western medicine in patients

with lower frequency of angina attack effect is better than that in the control group, as shown in Figure 3.

3.4.2. Duration of Angina Attack. There were 5 studies [6, 8, 10, 13, 27] that observed the duration of angina attack. The heterogeneity test (P = 0.37,  $I^2 = 6\%$ ) indicated that there was small heterogeneity between the studies; therefore, a fixed-effects model was used for the meta-analysis, and the results showed a statistically significant difference (MD = -3.36, 95% CI [-3.69, -3.03], P < 0.00001), suggesting that the Shuxuening injection combined with conventional Western medicine in patients with reduced duration of angina attack effect is better than that in the control group, as shown in Figure 4.

3.4.3. Nitroglycerin Dosage. 3 studies [17, 22, 27] observed the dosage of nitroglycerin. The heterogeneity test (P = 0.55,  $I^2 = 0\%$ ) indicated that there was small heterogeneity between the studies; therefore, a fixed-effects model was used for the meta-analysis, and the results showed a statistically significant difference (MD = -0.39, 95% CI [-0.65, -0.13], P = 0.003), suggesting that the Shuxuening injection combined with conventional Western medicine in patients with less dosage of nitroglycerin effect is better than that in the control group, as shown in Figure 5.

3.4.4. Improvement of ECG. 13 studies [7, 12, 14–16, 20–23, 29, 31–33] observed the electrocardiogram improvement in the study literature. The heterogeneity test (P = 0.68,  $I^2 = 0\%$ ) indicated that there was small heterogeneity between the studies; therefore, a fixed-effects model was used for the meta-analysis, and the results show that the difference is statistically significant (RR = 1.31, 95% CI [1.23, 1.40], P < 0.00001), suggesting that the Shuxuening injection combined with conventional Western medicine in patients with role of the electrocardiogram improvement is better than that in control group, as shown in Figure 6.

3.4.5. Clinical Efficacy of Angina. 25 studies [7, 9–21, 23–33] observed the angina clinical curative effect. The heterogeneity test (P = 0.97,  $I^2 = 0\%$ ) indicated that there was small heterogeneity between the studies; therefore, a fixed-effects model was used for the meta-analysis, and the results show that the difference is statistically significant (RR = 1.23, 95% CI [1.19, 1.27], P < 0.00001), suggesting that the Shuxuening injection combined with conventional Western medicine in improving patients with angina clinical curative effect is better than that in control group, as shown in Figure 7.

3.4.6. Blood Fat. 3 studies [11, 16, 29] observed the triglyceride (TG), and the heterogeneity test showed that there was significant heterogeneity among the results of studies (P < 0.0001,  $I^2 = 89\%$ ); therefore, a random-effects model was used for the meta-analysis, and the results show a statistically significant difference (MD = -0.72, 95% CI [-1.05, -0.38], P < 0.0001), suggesting that the Shuxuening injection combined with conventional Western medicine in

TABLE 1: Literature search	h.
----------------------------	----

Study IDs	San si:	nple ze	Duration	Intervention		А	ge	Ger	nder	Outcomes
	Т	С	(days)	Т	С	Т	С	М	F	
Chen and Sun 2018 [6]	33	33	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	58.1 ± 2.0	$57.8 \pm 2.4$	_	_	3
Qiu 2018 [7]	30	30	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$72.4 \pm 2.3$	$70.9 \pm 2.2$	24	36	189
Liu 2018 [8]	40	40	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$58.76 \pm 4.50$	58.90 ± 4.72	46	34	2356
Zhang 2017 [9]	42	40	30	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$55\pm 6$	53 ± 9	48	34	1
Wu 2016 [10]	40	40	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$61.2 \pm 3.1$	$61.5 \pm 3.2$	49	31	12356
Zheng and Li 2015 [11]	49	49	20	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	43	55	167
Li et al. 2015 [12]	36	36	28	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$64.3 \pm 1.2$	63.1 ± 1.3	39	33	18
Liu 2015 [13]	42	42	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$60.5 \pm 3.2$	$61.3 \pm 3.4$	49	35	123569
Liu and Cheng 2015 [14]	48	48	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	59.38±6.22	54.87 ± 4.95	57	39	158
Zhu 2014 [15]	48	48	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	63.8±11.2	$64.1\pm10.8$	56	40	168
He et al. 2014 [16]	62	60	28	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	55.80 ± 3.14	52.80 ± 2.90	63	59	15789
Zhang 2013 [17]	42	40	15	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$54\pm8$	55 ± 8	48	34	14
Liu and Zhang 2013 [18]	50	50	14	Basic care + Shuxueninginjection25 ml, ivgtt, qd	Basic care	58.7 ± 6.5	57.9 ± 5.3	53	47	166
Geng 2013 [19]	26	26	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	59.5±7.6	58.2±8.3	29	23	19
Lei and Xiao 2013 [20]	50	50	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	56.3 ± 2.6	55.6 ± 2.5	70	30	189
Liu and Wei 2013 [21]	60	60	14	Basic care + Shuxueninginjection10 ml, ivgtt, qd	Basic care	_	_	62	58	189
Ma and Yao 2012 [22]	53	49	10	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	68.79±10.31	$68.12 \pm 10.27$	67	35	489
Tao and Chen 2012 [23]	36	32	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	36	32	189
Zhuang 2012 [24]	34	34	14	Basic care + Shuxueninginjection10 ml, ivgtt, qd	Basic care	_	_	41	27	19

Study IDs	Sam siz	iple ze	Duration	Intervention		Aş	ge	Gen	der	Outcomes
1	Т	С	(days)	Т	С	Т	С	М	F	
Yan 2011 [25]	68	68	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	76	60	19
Sui 2011 [26]	30	30	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	36	24	125
Gao and Feng 2011 [27]	36	33	15	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	43	26	12349
Li 2011 [28]	400	400	15	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	58.20 ± 5.90	58.70 ± 6.20	430	370	1
Chai 2010 [29]	58	42	7	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	64.3±2.3	62.6±1.9	64	36	0789
Guo 2010 [30]	30	30	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	_	_	19
Wang 2010 [31]	45	45	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	_	_	_	_	189
Zhang et al. 2008 [32]	48	48	15	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$63.8 \pm 11.2$	$64.1\pm10.8$	54	42	189
Xi 2009 [33]	48	40	14	Basic care + Shuxueninginjection20 ml, ivgtt, qd	Basic care	$56.3 \pm 7.8$	$55.1 \pm 4.5$	50	38	189

TABLE 1: Continued.

Note: ①: clinical effect of angina; ②: angina frequency; ③: duration of angina; ④: nitroglycerin dosage; ⑤: C-reactive protein; ⑥: brain natriuretic peptide; ⑦: blood fat; ⑧: improvement of electrocardiogram; ⑨: adverse drug reactions or adverse events.

Zhuang 2012	Zhu 2014	Zheng 2015	Zhang 2017	Zhang 2013	Zhang 2008	Yan 2011	Xi 2009	Wu 2016	Wang 2010	Tao 2012	Sui 2011	Ma 2012	Liu 2018	Liu 2015	Liu 2013	Li 2015	Li 2015	Li 2013	Li 2011	Lei 2013	He 2014	Guo 2010	Geng 2013	Gao 2011	Chou 2018	Chen 2018	Chai 2010	
?	?	?	?	?	?	?	?	Ŧ	?	?	?	?	?	Ŧ	?	+	?	+	?	?	?	?	?	?	?	?	?	Random sequence generation (selection bias)
?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	Allocation concealment (selection bias)
?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	Blinding of participants and personnel (performance bias)
?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	Blinding of outcome assessment (detection bias)
+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	Ŧ	Ŧ	Ŧ	Ŧ	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	Ŧ	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	Incomplete outcome data (attrition bias)
+	+	Ŧ	+	+	Ŧ	+	+	Ŧ	+	÷	Ŧ	+	+	Ŧ	Ŧ	+	+	+	+	+	Ŧ	Ŧ	+	+	Ŧ	Ŧ	+	Selective reporting (reporting bias)
?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	Other bias



Study or Subgroup	Exj	perime	ntal		Control	l	Weight	Mean Difference		Me	an Differe	ence	
Study of Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Random, 95% CI		IV, R	andom, 95	5% CI	
Gao 2011	1.26	0.82	36	1.6	1.17	33	19.3	-0.34 [-0.82, 0.14]					
Liu 2015	1.6	0.8	42	2.8	1.2	42	19.7	-1.20 [-1.64, -0.76]			-		
Liu 2018	1.6	0.78	40	2.82	1.25	40	19.5	-1.22 [-1.68, -0.76]			-		
Sui 2011	1.73	0.39	30	3.87	0.58	30	21.2	-2.14 [-2.39, -1.89]		-			
Wu 2016	1.5	0.4	40	2.9	1.1	40	20.3	-1.40 [-1.76, -1.04]		-			
Total (95% CI)			188			185	100.0	-1.28 [-1.88, -0.67]		•			
Heterogeneity: $Tau^2 = 0$ .	44; Chi <sup>2</sup> = 5	0.84, df	f = 4 (P + 1)	< 0.0000	1); $I^2 =$	92%		_	1			1	
Test for overall effect: Z	= 4 13 (P < (	0001)							-4	-2	0	2	4
										Т		С	

FIGURE 3: Meta-analysis of angina frequency.

Studer on Sub moun	Exp	oerime	ntal	(	Contro	1	Weight	Mean Difference		Ν	Aean Differe	ence	
Study of Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI		Γ	V, Fixed, 959	6 CI	
Chen 2019	3.6	0.8	33	7	1.9	33	22.1	-3.40 [-4.10, -2.70]		_			
Gao 2011	2.2	1.6	36	5.9	1.4	33	21.8	-3.70 [-4.41, -2.99]					
Liu 2015	3.9	1.2	42	6.8	2.3	42	17.8	-2.90 [-3.68, -2.12]		<u> </u>			
Liu 2018	3.92	1.2	40	6.83	2.35	30	16.4	-2.91 [-3.73, -2.09]		<u> </u>			
Wu 2016	3.4	0.9	40	7.1	2.1	40	21.8	-3.70 [-4.41, -2.99]					
Total (95% CI)			191			188	100.0	-3.36 [-3.69, -3.03]	•				
Heterogeneity: $Chi^2 = 4$	.27, df = 4	(P = 0.	37); $I^2 =$	6%					1	1		1	
Tost for overall effects 7	- 10 01 (D	< 0.00	001)						-4	-2	0	2	4
Test for overall effect; Z	– 19.91 (F	< 0.00	(1001)							Т		С	
Total (95% CI) Heterogeneity: $\text{Ch}^2 = 4$ Test for overall effect: Z	27, df = 4 = 19.91 (P	( <i>P</i> = 0.	191 37); I <sup>2</sup> =	6%		188	100.0	-3.36 [-3.69, -3.03]	-4	-2 T	0	2 C	

FIGURE 4: Meta-analysis of duration of angina.

Study or Subgroup	Exj	perime	ntal	(	Contro	1	Weight	Mean Difference		Me	an Differe	ence	
Study of Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI		IV,	Fixed, 95%	6 CI	
Gao 2011	1	1.86	36	1.3	0.9	33	38.8	-0.30 [-0.72, 0.12]					
Ma 2012	0.76	0.71	52	1.16	1.02	49	56.5	-0.40 [-0.74, -0.06]		_			
Zhang 2013	2.8	2.7	42	3.8	2.8	40	4.7	-1.00 [-2.19, 0.19]					
Total (95% CI)			130			122	100.0	-0.39 [-0.65, -0.13]		•			
Heterogeneity: $Chi^2 = 1.1$	9, df = 2	(P = 0.1)	55); $I^2 =$	0%				-				1	
Test for overall effect: $Z =$	2.95 (P	= 0 003	)						-2	-1	0	1	2
	2.55 (1	0.000	,							Т		С	

FIGURE 5: Meta-analysis of nitroglycerin dosage.

Study or Subgroup	Experin Events	mental Total	Cor Events	trol Total	Weight (%)	Risk Ratio M-H, Fixed, 95% CI		Risk M-H, Fix	Ratio ed, 95% CI		
Chai 2010	54	58	31	42	9.2	1.26 [1.04, 1.53]					
Chou 2018	29	30	26	30	6.7	1.12 [0.95, 1.30]			<b></b>		
He 2014	44	62	33	60	8.6	1.29 [0.98, 1.71]			<b></b>		
Lei 2013	46	50	35	50	9.0	1.31 [1.08, 1.60]					
Li 2015	26	36	21	36	5.4	1.24 [0.88, 1.74]					
Li 2015	41	48	32	48	8.2	1.28 [1.02, 1.62]					
Liu 2013	52	60	35	60	9.0	1.49 [1.17, 1.88]				_	
Ma 2012	49	53	37	49	9.8	1.22 [1.03, 1.46]					
Tao 2012	26	36	17	32	4.6	1.36 [0.93, 1.99]		-			
Wang 2010	40	45	31	45	7.9	1.29 [1.03, 1.61]					
Xi 2009	36	48	16	40	4.5	1.88 [1.24, 2.83]				-	→
Zhang 2008	43	48	34	48	8.7	1.26 [1.03, 1.55]					
Zhu 2014	43	48	33	48	8.5	1.30 [1.05, 1.61]					
Total (95% CI)		622		588	100.0	1.31 [1.23, 1.40]			•		
Total events	529		381								
Heterogeneity: $Chi^2 = 9$	.31, df = 12	2 (P = 0.6)	58); $I^2 = 0$ %	6			0.5	0.7	1 1.5	2	_
Test for overall effect: Z	= 7.99 (P -	< 0.00001	1)					С	Т		

FIGURE 6: Meta-analysis of the improvement of electrocardiogram.

patients with lower triglycerides effect is better than that in the control group; 3 studies [11, 16, 29] observed the total cholesterol (TC), and the heterogeneity test showed that there was significant heterogeneity among the results of studies (P < 0.0001,  $I^2 = 89\%$ ); therefore, a random-effects model was used for the meta-analysis, and the results show a statistically significant difference (MD = -1.39, 95% CI [-1.84, -0.94], P < 0.00001), suggesting that the Shuxuening injection combined with conventional Western medicine in patients with lower total cholesterol effect is better than that in the control group; 3 studies [11, 16, 29] observed the lowdensity lipoprotein cholesterol (LDL-C), and the heterogeneity test showed that there was significant heterogeneity among the results of studies (P < 0.00001,  $I^2 = 98\%$ ); therefore, a random-effects model was used for the meta-analysis, and the results showed a statistically significant difference (MD = -1.20, 95% CI [-2.12, -0.29], P = 0.01), suggesting that the Shuxuening injection combined with conventional Western medicine in patients with lower LDL cholesterol effect is better than that in the control group; 3 studies Evidence-Based Complementary and Alternative Medicine

Study or Subgroup	Experin	mental Total	Cor Events	itrol Total	Weight	Risk Ratio M-H Fixed 95% CI	Risk Ratio M-H Fixed 95% CI	
	Lvents	Iotai	Lvents	IOtal	(70)	WI-11, 11ACU, 9570 CI		
Chai 2010	54	58	28	42	3.0	1.40 [1.12, 1.75]		
Chou 2018	29	30	27	30	2.5	1.07 [0.94, 1.23]		
Gao 2011	34	36	27	33	2.6	1.15 [0.96, 1.38]		
Geng 2013	24	26	19	26	1.8	1.26 [0.98, 1.64]		
Guo 2010	29	30	24	30	2.2	1.21 [1.00, 1.46]		
He 2014	56	62	48	60	4.5	1.13 [0.97, 1.31]		
Lei 2013	45	50	37	50	3.4	1.22 [1.01, 1.47]		
Li 2015	29	36	23	36	2.1	1.26 [0.94, 1.69]		
Li 2011	380	400	310	400	28.7	1.23 [1.16, 1.30]		
Li 2013	45	50	36	50	3.3	1.25 [1.03, 1.52]		
Li 2015	44	48	36	48	3.3	1.22 [1.02, 1.47]		
Liu 2013	54	60	49	60	4.5	1.10 [0.95, 1.28]		
Liu 2015	39	42	32	42	3.0	1.22 [1.01, 1.47]		
Sui 2011	27	30	24	30	2.2	1.13 [0.91, 1.39]		
Tao 2012	34	36	25	32	2.4	1.21 [0.99, 1.48]		
Wang 2010	43	45	32	45	3.0	1.34 [1.10, 1.64]		
Wu 2016	38	40	31	40	2.9	1.23 [1.02, 1.47]		
Xi 2009	46	48	31	40	3.1	1.24 [1.04, 1.48]		
Yan 2011	63	68	50	68	4.6	1.26 [1.08, 1.47]		
Zhang 2008	44	48	35	48	3.2	1.26 [1.04, 1.52]		
Zhang 2013	38	42	29	40	2.7	1.25 [1.01, 1.55]		
Zhang 2017	39	42	29	40	2.7	1.28 [1.04, 1.58]		
Zheng 2015	43	49	30	49	2.8	1.43 [1.12, 1.83]		_
Zhu 2014	42	48	33	48	3.1	1.27 [1.02, 1.58]		
Zhuang 2012	32	34	24	34	2.2	1.33 [1.06, 1.68]	— — —	
Total (95% CI)		1458		1421	100.0	1.23 [1.19, 1.27]	•	
Total events	1351		1069					
Heterogeneity: $Chi^2 = 1$	3.00, df =	24 ( <i>P</i> =	$0.97); I^2 =$	0%		0.5	0.7 1 1.5	2
Test for overall effect: Z	= 12.35 (I	P < 0.000	001)			0.5	C T	2

FIGURE 7: Meta-analysis of clinical efficacy of angina.

[11, 16, 29] observed the high-density lipoprotein cholesterol (HDL-C), and the heterogeneity test showed that there was significant heterogeneity among the results of studies (P < 0.00001,  $I^2 = 99\%$ ); therefore, a random-effects model was used for the meta-analysis, and the results showed no significant statistical significance (MD = 0.49, 95% CI [-0.06, 1.04], P = 0.08), suggesting that the Shuxuening injection combined with conventional Western medicine had the same effect on raising high-density lipoprotein cholesterol as the control group, as shown in Figure 8.

3.4.7. C-Reactive Protein. 9 studies [8, 10, 11, 13–16, 18, 26] observed the C-reactive protein, and the heterogeneity test showed that there was significant heterogeneity among the results of studies (P < 0.00001,  $I^2 = 88\%$ ); therefore, a random-effects model was used for the meta-analysis, and the results showed a statistically significant difference (MD = -2.72, 95% CI [-3.41, -2.03], P < 0.00001), suggesting that the Shuxuening injection combined with conventional Western medicine in improving patients with the role of C-reactive protein is superior to that in the control group, as shown in Figure 9.

3.4.8. Brain Natriuretic Peptide (BNP). 4 studies [8, 10, 13, 18] observed the brain natriuretic peptide. The heterogeneity test (P = 0.99,  $I^2 = 0\%$ ) indicated that there was

small heterogeneity between the studies; therefore, a fixedeffects model was used for the meta-analysis, and the results showed a statistically significant difference (MD = -23.33, 95% CI [-27.87, -18.79], P < 0.00001), suggesting that the Shuxuening injection combined with conventional Western medicine in patients with reducing effect of brain natriuretic peptide is superior to that in the control group, as shown in Figure 10.

3.4.9. Adverse Reactions. 16 studies [7, 13, 16, 19–25, 27, 29–33] observed the adverse reactions, including 9 documents, as shown in Table 2, and the heterogeneity test (P = 1.00, I2 = 0%) indicated that there was small heterogeneity between the studies; therefore, a fixed-effects model was used for the meta-analysis, and the results showed no significant statistical significance (RR = 0.99, 95% CI [0.54, 1.81], P = 0.97) and showed quite adverse reactions occurring between the two groups, as shown in Figure 11.

3.5. Risk Assessment of Bias. For more than 10 of the included works of literature, the risk of publication bias was assessed. The funnel plot of clinical efficacy and ECG improvement outcome index of angina pectoris was observed. The results showed the incomplete symmetry between left and right, suggesting the risk of publication bias, which may

Study or Subgroup	Expe Mean	erimen SD	tal Total	Co Mean	ntrol SD	Total	Weight (%)	Mean Difference IV, Random, 95% CI		Mean Dif IV, Random	ference 1, 95% CI		_
1.8.1 TC													_
Chai 2010	4.04	1.02	58	5.82	1.03	42	8.1	-1.78 [-2.19, -1.37]		-			
He 2014	4.2	0.85	62	5.68	0.55	60	8.3	-1.48 [-1.73, -1.23]	_	_			
Zheng 2015	3.68	0.41	49	4.68	0.39	49	8.4	-1.00 [-1.16, -0.84]		-			
Subtotal (95% CI)			169			151	24.8	-1.39 [-1.84, -0.94]					
Heterogeneity: $Tau^2 = 0.14$ ;	$Chi^2 =$	18.60,	df = 2 (P	< 0.0001	1); $I^2 = 1$	89%							
Test for overall effect: $Z = 6$	.03 (P <	0.0000	)1)										
1.8.2 TG													
Chai 2010	1.47	0.03	58	2.3	0.27	42	8.4	-0.83 [-0.91, -0.75]		-			
He 2014	0.95	0.62	62	1.96	0.65	60	8.3	-1.01 [-1.24, -0.78]		_			
Zheng 2015	1.62	0.68	49	1.88	0.71	49	8.3	-0.26 [-0.54, 0.02]					
Subtotal (95% CI)			169			151	25.0	-0.72 [-1.05, -0.38]					
Heterogeneity: $Tau^2 = 0.08$ ;	Chi <sup>2</sup> =	18.58,	df = 2 (P	< 0.000	(1); $I^2 = 3$	89%				•			
Test for overall effect: $Z = 4$	.20 (P <	0.0001	1)		,,,								
1.8.3 LDL-C													
Chai 2010	3.4	0.5	58	5.5	0.7	42	8.3	-2.10 [-2.35, -1.85]					
He 2014	2.26	0.93	62	3.07	0.94	60	8.2	-0.81 [-1.14, -0.48]					
Zheng 2015	2.08	0.32	49	2.78	0.3	49	8.4	-0.70 [-0.82, -0.58]		-			
Subtotal (95% CI)			169			151	24.9	-1.20 [-2.12, -0.29]					
Heterogeneity: $Tau^2 = 0.63$ ;	$Chi^2 =$	99.34,	df = 2 (P	< 0.0000	()1); $I^2 =$	98%							
Test for overall effect: $Z = 2$	.58 (P =	0.010)											
1.8.4 HDL-C	1 50	0.01	50	0.07	0.04	10	0.4	0.05 [0.01, 0.02]					
Chai 2010	1.73	0.21	58	0.86	0.04	42	8.4	0.87 [0.81, 0.93]					
He 2014	1.57	0.42	62	0.96	0.43	60	8.4	0.61 [0.46, 0.76]			-		
Zheng 2015	1.22	0.34	49	1.23	0.31	49	8.4	-0.01 [-0.14, 0.12]		+			
Subtotal (95% CI)	2		169			151	25.2	0.49 [-0.06, 1.04]					
Heterogeneity: $Tau^2 = 0.23$ ;	Chi <sup>2</sup> =	153.57	df = 2(1)	P < 0.000	$(001); I^2$	= 99%							
Test for overall effect: $Z = 1$	.75 (P =	0.08)											
Total (95% CI)			676			604	100.0	-0.70 [-1.28, -0.13]					
Heterogeneity: $Tau^2 = 1.01$ ;	$Chi^2 = 1$	2265.8	8, $df = 11$	(P < 0.0)	)0001);	$I^2 = 100\%$	6	_		<del> </del>	1	1	-
Test for overall effect: $Z = 2$	.40 (P =	0.02)							-2	-1 0	1	2	
Test for subgroup difference	es: Chi <sup>2</sup>	= 28.2	5, df = 3	(P < 0.00)	0001), İ	$^{2} = 89.4\%$				Т	С		

FIGURE 8: Meta-analysis of blood fat.

	Ex	perime	ntal		Contro	1	Weight	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Random, 95% CI	IV, Random, 95% CI
He 2014	2.21	0.4	62	4.2	0.63	60	14.0	-1.99 [-2.18, -1.80]	
Li 2013	6	2.9	50	9.5	3.4	50	9.7	-3.50 [-4.74, -2.26]	
Li 2015	6.58	2.43	48	10.26	2.24	48	11.2	-3.68 [-4.61, -2.75]	
Liu 2015	6.5	2.3	42	9.8	3.7	42	9.3	-3.30 [-4.62, -1.98]	
Liu 2018	6.5	2.29	40	9.82	3.75	40	9.1	-3.32 [-4.68, -1.96]	
Sui 2011	4.67	1.32	30	6.89	1.59	30	12.2	-2.22 [-2.96, -1.48]	
Wu 2016	6.09	2.23	40	9.84	3.66	40	9.3	-3.75 [-5.08, -2.42]	
Zheng 2015	6.42	1.98	49	9.54	1.99	49	12.0	-3.12 [-3.91, -2.33]	
Zhu 2014	4.54	1.13	48	5.15	1.4	48	13.1	-0.61 [-1.12, -0.10]	-
Total (95% CI)			409			407	100.0	-2.72 [-3.41, -2.03]	•
Heterogeneity: $Tau^2 = 0$	.88; Chi <sup>2</sup> =	= 68.50,	df = 8 (1)	P < 0.0000	()1); $I^2 =$	= 88%			
Test for overall effect: 7	- 7 71 (P	< 0.000	01)						-4 $-2$ $0$ $2$ $4$
rest for overall effect. Z	- /./1 (F	< 0.000	,01)						Т С



Study or Subgroup	Ex Mean	perime SD	ntal Total	Mean	Contro SD	l Total	Weight (%)	Mean Difference IV, Fixed, 95% CI	Mean Difference IV, Fixed, 95% CI
Li 2013	77.2	23.9	50	101.4	22.5	50	24.9	-24.20 [-33.30, -15.10]	
Liu 2015	76.5	21.3	42	99.2	27.8	42	18.4	-22.70 [-33.29, -12.11]	
Liu 2018	76.52	12.18	40	99.3	20.54	40	37.6	-22.78 [-30.18, -15.38]	_ <b></b>
Wu 2016	75.26	20.27	40	99.16	26.73	40	19.1	-23.90 [-34.30, -13.50]	
Total (95% CI)			172			172	100.0	-23.33 [-27.87, -18.79]	•
Heterogeneity: $Chi^2 =$	0.08, df =	3(P = 0)	$(.99); I^2 =$	= 0%				_	
Test for overall effect:	Z = 10.07	( <i>P</i> < 0.0	0001)						-20 -10 0 10 20
									т с

Study IDs	Adverse reactions							
	Т	С						
Liu [13]2015	1 case of nausea, 2 cases of local swelling, and 1 case of mild headache	1 case of nausea, 1 case of local swelling, and 1 case of mild headache						
He et al. [16]2014	1 case of mild elevation of alanine aminotransferase (<50 U)	1 case of mild elevation of alanine aminotransferase (<50 U)						
Geng [19]2013	Facial flushing occurred in 2 cases and dry mouth in 2 cases	1 case of dry mouth, 1 case of diarrhea, and 1 case of dizziness						
Lei and Xiao [20] 2013	2 cases of skin rash	2 cases of skin rash						
Ma and Yao [22] 2012	Three patients presented with nausea and one with abdominal distension	Two patients developed nausea and one had palpitation						
Tao and Chen [25] 2011	Flush appeared in 3 cases	Flush appeared in 3 cases						
Gao and Feng [27] 2011	One case had mild headache, head distension, and flushed face	Two patients had mild headache, head distension, and flushed face						
Chai [29]2010	Patchy ecchymosis appeared at the injection site in 2 cases	Patchy ecchymosis appeared at the injection site in 3 cases						
Xi [33]2009	Flushing and dizziness were observed in 2 patients	Flushing and dizziness were observed in 2 patients						

TABLE 2: Adverse reactions.

Study or Subgroup	Experii Events	nental Total	Con Events	trol Total	Weight (%)	Risk Ratio M-H, Fixed, 95% C	CI	Risk Ratio M-H, Fixed, 95% CI		% CI	
Chai 2010	2	58	3	42	17.7	0.48 [0.08, 2.75]	_				
Gao 2011	1	36	1	33	5.3	0.92 [0.06, 14.07]					
Geng 2013	4	26	3	26	15.3	1.33 [0.33, 5.38]					
He 2014	1	62	1	60	5.2	0.97 [0.06, 15.12]			_		
Lei 2013	2	50	2	50	10.2	1.00 [0.15, 6.82]			_		
Liu 2015	3	42	3	42	15.3	1.00 [0.21, 4.67]					
Ma 2012	4	53	3	49	15.9	1.23 [0.29, 5.23]					
Xi 2009	2	48	2	0		Not estimable					
Yan 2011	3	68	3	68	15.3	1.00 [0.21, 4.78]					
Total (95% CI)		443		370	100.0	0.99 [0.54, 1.81]			$\checkmark$		
Total events	22		21						1		
Heterogeneity: $\text{Chi}^2 = 0.92$ , $\text{df} = 7$ ( $P = 1.00$ ); $I^2 = 0\%$						1	1				
Test for overall effect: $Z = 0.03$ ( $P = 0.97$ )						0.05	0.2	1	5	20	
								Т		С	

FIGURE 11: Meta-analysis of adverse reactions.

be related to the quality of the included literature and the size of the sample, as shown in Figures 12 and 13.

#### 4. Discussions

4.1. Research Results. The main purpose of this study is to observe the clinical efficacy of Shuxuening injection in the treatment of unstable angina pectoris. The results showed that the integrative therapy was better than the solo conventional Western medicine in the unstable angina including the improvement of clinical curative effect and the reduction in the frequency of angina, angina duration, dosage of nitroglycerin, CRP, the BNP, lower triglyceride, total cholesterol, and low-density lipoprotein cholesterol. There is no significant difference in the incidence of adverse reactions. The clinical application of the integrative therapy in the treatment of unstable angina has clear efficacy and certain safety, providing more evidencebased evidence for the clinical application of Shuxuening injection in the future.

4.2. Research Significance. The Shuxuening injection consists of the active components of Ginkgo leaf extract, which include flavone glycosides and terpenoids, and it can affect oxidation reaction, remove oxide free radical, improve blood flow state, inhibit platelet aggregation, and promote vascular smooth muscle relaxation [34]. The Shuxuening injection with multicomponents and multi-targets is an encouraging complementary to the Western medicine treatment in the unstable angina, especially to improve the survival rate and quality of life of patients. The adverse reactions of the integrative therapy were recorded in detail to help the clinical practice to prescribe.



FIGURE 12: Funnel plot of clinical efficacy of angina.



FIGURE 13: Funnel plot of ECG improvement.

4.3. Limitations of the Study. Our study is to evaluate the efficacy and safety of the integrative therapy in the treatment of unstable angina; meanwhile, it also has the following limitations: firstly, in 28 papers, only four studies were allocated using a random number table, and the rest of the 24 studies just mentioned the randomization without description. There is no mention of allocation concealment and blinding in any of the included literature. All studies have no shedding or withdrawal. Secondly, most of the included studies, and the sample size was small. Only one study had a large sample size of 500 patients, but the calculation method of the sample size was not explained. Thirdly, conventional Western drugs were not described in detail in the included studies, which attributed to the study heterogeneity.

4.4. Thinking about the Future. Investigators need to include high-quality clinical randomised controlled trials in future. That is a key factor to improve the level of evidence. For the implementation of specific solutions to clear the random method, estimation of sample size, allocation concealment and blinding, attrition bias, and records of the adverse reactions during the study period should be paid more attention. The clinical study register is important too. TCM Evidence-Based Complementary and Alternative Medicine

treatment should be based on syndrome differentiation, and TCM syndrome types should be specifically stipulated in the inclusion criteria so as to more improve the quality of life and prognosis of patients.

### 5. Conclusion

It is concluded that the Shuxuening injection combined with conventional Western medicine could improve the onset of unstable angina frequency, reduce the dosage of nitroglycerin, and improve ECG, the blood lipid, CRP, and BNP, but the quality of all included studies was low, so the more higher quality of clinical randomized controlled trials will be needed to further demonstrate the validity of Shuxuening injection combined with conventional Western medicine in the unstable angina.

#### **Data Availability**

The data are available from PubMed, EMBASE, Cochrane Library, VIP, CNKI, Wanfang Database, and China Biomedical Database.

#### **Conflicts of Interest**

The authors declare no conflicts of interest regarding the publication of this article.

#### Acknowledgments

This work was supported by the National Science and Technology Major Project (2018ZX09734-002) and the National Natural Science Foundation of China (81803930).

#### References

- Y. Shen, G. He, T. Xiao, and L. Yu, "New progress in the diagnosis and treatment of unstable angina," *Popular Science* and *Technology*, vol. 21, no. 11, pp. 51–53, 2019.
- [2] J. A. Ambrose and G. Dangas, "Unstable Angina," Archives of Internal Medicine, vol. 160, no. 1, pp. 25–37, 2000.
- [3] L. Zhang, J. Zhang, and S. Luo, "Changes in interleukin-27 levels in patients with acute coronary syndrome and their clinical significance," *PeerJ*, vol. 7, Article ID e5652, 2019.
- [4] S. Hu, "Clinical application and safe use of Shuxuening injection," *Journal of Hunan University of Chinese Medicine*, vol. 32, no. 11, pp. 78–81, 2012.
- [5] J. P. T. Higgins, D. G. Altman, and P. C. Gotzsche, "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials," *BMJ*, vol. 343, Article ID d5928, 2011.
- [6] Z. Chen and Y. Sun, "Study on the therapeutic effect of Shuxuening injection on unstable angina with acute coronary syndrome," *Capital food and medicine*, vol. 26, no. 16, p. 60, 2019.
- [7] J. Qiu, "Discussion on the effect of Shuxuening injection on the expression of basic fibroblast growth factor in serum of patients with unstable angina," *Gems of Health*, vol. 30, no. 9, 2018.
- [8] J. Liu, "Shuxuening injection in the treatment of 40 cases of unstable angina with acute coronary syndrome," *Chinese Community Doctors*, vol. 34, no. 27, pp. 82–84, 2008.

- [9] Z. Zhang, "Clinical observation on the treatment of unstable angina by Shuxuening injection," Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine, vol. 5, no. 31, pp. 49–52, 2017.
- [10] L. Wu, "Clinical study of Shu Xuening in patients with unstable angina with acute coronary syndrome," *Medical Journal* of Chinese People's Health, vol. 28, no. 9, pp. 64-65, 2016.
- [11] G. Zheng and B. Li, "Clinical efficacy of Shuxuening injection combined with atorvastatin in the treatment of unstable angina and its influence on serum Hs-CRP," *Shaanxi Journal* of *Traditional Chinese Medicine*, vol. 36, no. 9, pp. 1120-1121, 2015.
- [12] C. Li, J. Cheng, C. Zhang, and Y. Zhang, "Clinical efficacy of Shuxuening injection combined with atorvastatin in the treatment of unstable angina and its influence on serum Hs-CRP," *Shaanxi Journal of Traditional Chinese Medicine*, vol. 36, no. 7, pp. 816-817, 2015.
- [13] Y. Liu, "Observation on the clinical effect of Shuxuening injection in the treatment of unstable angina with acute coronary syndrome," *China Modern Medicine*, vol. 22, no. 17, pp. 152–154, 2015.
- [14] X. Liu and J. Cheng, "Treatment of 48 cases of unstable angina by shuxuening injection," *Henan Traditional Chinese Medicine*, vol. 35, no. 4, pp. 728–730, 2015.
- [15] C. Zhu, "Shuxuening injection in the treatment of unstable angina and its effect on serum HS-CRP," *Shaanxi Medical Journal*, vol. 43, no. 12, pp. 1672-1673, 2014.
- [16] X. He, F. Zheng, and J. Huang, "Clinical observation of Shuxuening injection combined with Rosuvastatin in the treatment of unstable angina," *Chinese Journal of Modern Applied Pharmacy*, vol. 31, no. 5, pp. 606–609, 2014.
- [17] C. Zhang, "Clinical observation of shuxuening injection in the treatment of unstable angina," *Guide of China Medicine*, vol. 11, no. 32, pp. 203-204, 2013.
- [18] L. Liu and W. Zhang, "Effects of Shuxuening injection on serum BNP, Hs-CRP and carotid atherosclerotic plaque in patients with unstable angina," *China Modern Doctor*, vol. 51, no. 14, pp. 73–75, 2013.
- [19] Y. Geng, "Clinical efficacy observation of Shuxuening Injection in the treatment of 26 cases of angina," *The Medical Forum*, vol. 17, no. 14, pp. 1803-1804, 2013.
- [20] R. Lei and W. Xiao, "Observation on the curative effect of Shuxuening for unstable angina," *Journal of Yangtze Uni*versity(Natural Science Edition), vol. 10, no. 12, pp. 4-5, 2013.
- [21] G. Liu and A. Wei, "Clinical observation of shuxuening injection in the treatment of unstable angina with coronary heart disease," *Guide of China Medicine*, vol. 11, no. 2, pp. 284-285, 2013.
- [22] S. Ma and X. Yao, "Clinical study of Shuxuening injection combined with Western medicine in the treatment of unstable angina," *Chinese Journal of Ethnomedicine and Ethnopharmacy*, vol. 21, no. 11, pp. 92–94, 2012.
- [23] L. Tao and M. Chen, "Analysis of the therapeutic effect of Shuxuening injection on unstable angina," *Journal of Liaoning University of Traditional Chinese Medicine*, vol. 14, no. 5, pp. 45-46, 2012.
- [24] Z. Zhuang, "Efficacy and safety of shuxuening injection in the treatment of unstable angina," *China Health Industry*, vol. 9, no. 10, p. 65, 2012.
- [25] S. Yan, "Effect of shuxuening injection on unstable angina," *Chinese Journal of Misdiagnostics*, vol. 11, no. 34, p. 8370, 2011.

- [26] L. Sui, "Effect of Shuxuening injection combined with low molecular weight heparin on unstable angina," *Guide of China Medicine*, vol. 9, no. 30, pp. 341-342, 2011.
- [27] H. Gao and X. Feng, "Effect of Shuxuening injection combined with isosorbide mononitrate on unstable angina," *Chinese Community Doctors*, vol. 13, no. 27, p. 179, 2011.
- [28] Z. Li, "Observation of curative effect and side effect of Shuxuening injection on 400 cases of unstable angina," *Guide* of China Medicine, vol. 9, no. 23, pp. 129-130, 2011.
- [29] J. Chai, "Clinical observation of shuxuening combined with western medicine in the treatment of 58 cases of unstable angina," *Fujian Journal of Traditional Chinese Medicine*, vol. 41, no. 3, pp. 20-21, 2010.
- [30] Y. Guo, "Clinical observation of shuxuening in the treatment of senile unstable angina," *Contemporary Medicine*, vol. 16, no. 20, pp. 146-147, 2010.
- [31] Y. Wang, L. Zhang, and M. Cheng, "Therapeutic effect of Shuxuening injection combined with low molecular weight heparin on unstable angina," *Huaihai Medicine*, vol. 28, no. 5, p. 449, 2010.
- [32] H. Zhang, H. Wan, and M. Sun, "Analysis of therapeutic effect of Shuxuening on unstable angina," *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 18, no. 5, p. 524, 2009.
- [33] H. Xi, "Clinical observation of shuxuaining injection in the treatment of unstable angina," *Henan Traditional Chinese Medicine*, vol. 29, no. 9, pp. 918-919, 2009.
- [34] Y. W. Wang, M. Gaom, and K. Shu, "The study of Plasma homocysteine levels and coronary heart disease," *Modern Laboratory Medicine*, vol. 23, no. 1, p. 82, 2008.